Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
826 stopped studies mapped to Malignant Female Reproductive System Neoplasm and descendants · 86% state a reason
Over the 826 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01312376 | Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer | Phase 1 | terminated | Mar 10, 2011 | Abramson Cancer Center at Penn Medicine | not stated | Not stated |
| NCT02452775 | Autologous OC-L Vaccine and Ovarian Cancer | Phase 1 | terminated | May 25, 2015 | Abramson Cancer Center at Penn Medicine | not stated | Not stated |
| NCT04132349 | Ulipristal Acetate in Symptomatic Uterine Fibroid | Phase 4 | terminated | Oct 18, 2019 | Mỹ Đức Hospital | Ulipristal Acetate was recalled | Other (stated, no rule matched) |
| NCT03286062 | VM110 in Detection of Microscopic Tumors: A Phase I Study | Phase 1 | terminated | Sep 18, 2017 | Fox Chase Cancer Center | Slow accrual | Enrollment / accrual |
| NCT01019278 | Proton Beam Radiation Therapy and Cisplatin in Treating Patients With Stage IB, Stage II,… | Phase 2 | withdrawn | Nov 24, 2009 | Abramson Cancer Center at Penn Medicine | not stated | Not stated |
| NCT02769546 | Physician-Patient Communication and Expectations Regarding Ovarian Cancer Prognosis | — | terminated | May 11, 2016 | Abramson Cancer Center at Penn Medicine | not stated | Not stated |
| NCT01847677 | Neoadjuvant Therapy in Advanced Ovarian Cancer With Avastin(NOVA) | Phase 2 | terminated | May 7, 2013 | Grupo Español de Investigación en Cáncer de Ovario | not stated | Not stated |
| NCT02713984 | A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer | Phase 1 / Phase 2 | withdrawn | Mar 21, 2016 | Zhi Yang | Reform CAR structure due to safety consideration | Safety / toxicity |
| NCT03644459 | Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101 | Phase 1 | withdrawn | Aug 23, 2018 | Lynkcell Inc. | Unable to recruit individuals for the study | Enrollment / accrual |
| NCT02665962 | Evaluating the Effect of Perioperative Caloric Restriction Program on Perioperative… | N/A | terminated | Jan 28, 2016 | Abramson Cancer Center at Penn Medicine | Poor enrollment | Enrollment / accrual |
| NCT02351089 | Probiotics in Radiation-treated Gynecologic Cancer(ProRad) | N/A | terminated | Jan 30, 2015 | Probi AB | Slow recruitment | Enrollment / accrual |
| NCT02452424 | A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and… | Phase 1 / Phase 2 | terminated | May 22, 2015 | Daiichi Sankyo | Terminated early for insufficient evidence of clinical efficacy | Efficacy / futility |
| NCT02487849 | HIPEC After Secondary Cytoreductive Operation in Patients With Platinum-sensitive…(HIPEC) | Phase 2 | withdrawn | Jul 2, 2015 | Krankenhaus Barmherzige Schwestern Linz | actually limited personnel ressources | Other (stated, no rule matched) |
| NCT00693342 | Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial… | Phase 3 | withdrawn | Jun 9, 2008 | Gynecologic Oncology Group | Never opened to accrual, a GOG working number, not developed into a clinical trial. | Enrollment / accrual |
| NCT01392352 | HYPAZ: Hypertension Induced by Pazopanib(HYPAZ) | Phase 2 | terminated | Jul 12, 2011 | Cambridge University Hospitals NHS Foundation Trust | Following DMC review, due to slow recruitment of evaluable patients. | Enrollment / accrual |
| NCT02576665 | A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients… | Phase 1 | terminated | Oct 15, 2015 | Tocagen Inc. | Sponsor decision | Sponsor / business decision |
| NCT03146039 | Non-Invasive Cervical Cancer Radiotherapy for Stage IB-IVB(NICER) | Phase 2 | withdrawn | May 9, 2017 | University of California, San Diego | Patient enrollment goal will not be met | Enrollment / accrual |
| NCT04125225 | What Are the Experiences of Patients With Pseudomyxoma Peritonei? | — | withdrawn | Oct 14, 2019 | University of Southampton | No participants enrolled. | Enrollment / accrual |
| NCT03466034 | The Role of Hypoxia as a Selective Pressure for TP53 Mutations | — | terminated | Mar 15, 2018 | Institute of Cancer Research, United Kingdom | Low numbers of eligible patients and failure to successfully recruit them. | Enrollment / accrual |
| NCT03699176 | Assessment of Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids(ASTEROID 7) | Phase 3 | withdrawn | Oct 9, 2018 | Bayer | No patient was recruited, study withdrawn for feasibility reasons. | Enrollment / accrual |
| NCT03852979 | Neo-Adjuvant Chemotherapy and Conservative Surgery in Cervical Cancer to Preserve…(NEOCON-F) | Phase 2 | terminated | Feb 25, 2019 | The Netherlands Cancer Institute | study is merged with CONTESSA study | Other (stated, no rule matched) |
| NCT00394602 | Chemoradiation-Induced Nausea and Emesis: Quality of Life | — | terminated | Nov 1, 2006 | M.D. Anderson Cancer Center | Requested by PI during yearly Continuing Review | Other (stated, no rule matched) |
| NCT00519272 | A Prospective Study Examining the Barriers to Care for Harris County Cervical Cancer… | — | terminated | Aug 22, 2007 | M.D. Anderson Cancer Center | Requested by PI during yearly Continuing Review | Other (stated, no rule matched) |
| NCT03300843 | Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients… | Phase 2 | terminated | Oct 4, 2017 | National Cancer Institute (NCI) | slow accrual | Enrollment / accrual |
| NCT01766622 | 18F-CP18 Imaging Studies for Cancer Treatment With Birinapant | Phase 2 | withdrawn | Jan 11, 2013 | National Institutes of Health Clinical Center (CC) | not stated | Not stated |
| NCT00924066 | Ixabepilone to Treat Cervical Cancer | Phase 2 | terminated | Jun 18, 2009 | National Cancer Institute (NCI) | Premature closure due to slow/insufficient accrual. | Enrollment / accrual |
| NCT00204997 | Preservation of Ovarian Function Via LOT in Squamous Cell Carcinoma of the Cervix | N/A | terminated | Sep 20, 2005 | University of Wisconsin, Madison | slow accrual | Enrollment / accrual |
| NCT00651716 | T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem… | — | terminated | Apr 3, 2008 | Vanderbilt-Ingram Cancer Center | Funding unavailable | Funding |
| NCT02661815 | A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer | Phase 1 | terminated | Jan 25, 2016 | Dana-Farber Cancer Institute | Company decided not to move forward with further accrual. | Enrollment / accrual |
| NCT03795272 | Rucaparib Maintenance Therapy in Advanced Cervical Cancer(MaRuC) | Phase 2 | withdrawn | Jan 7, 2019 | Nordic Society of Gynaecological Oncology - Clinical Trials Unit | Lack of financial support | Funding |
| NCT03281681 | A Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian…(REPROVe) | Phase 1 / Phase 2 | withdrawn | Sep 13, 2017 | DelMar Pharmaceuticals, Inc. | Alternate study design for ovarian cancer under discussion | Other (stated, no rule matched) |
| NCT01583686 | CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer | Phase 1 / Phase 2 | terminated | Apr 24, 2012 | National Cancer Institute (NCI) | Study terminated due to slow/insufficient accrual. | Enrollment / accrual |
| NCT02566811 | Selective Targeting of Adjuvant Therapy for Endometrial Cancer (STATEC)(STATEC) | N/A | terminated | Oct 2, 2015 | University College, London | Withdrawal of funding by CR UK due to poor recruitment | Enrollment / accrual |
| NCT04105465 | Study to Evaluate the Role of PlasmaJet in Patients Undergoing Groin Node Dissection for… | N/A | terminated | Sep 26, 2019 | Royal Surrey County Hospital NHS Foundation Trust | Conflict with another study that was opened to recruitment | Enrollment / accrual |
| NCT00484666 | Platinum-Resistant, Recurrent Epithelial Ovarian Cancer(TopoTxt) | — | withdrawn | Jun 11, 2007 | Carilion Clinic | PI withdrew from study protocol participation | Other (stated, no rule matched) |
| NCT03427073 | A Phase I Dose-escalation Study of Subcutaneous ALM201 in Patients With Advanced Ovarian… | Phase 1 | terminated | Feb 9, 2018 | Almac Discovery | to re-evaluate biomarker strategy for recruitment to Part 2 | Enrollment / accrual |
| NCT01834703 | Uterine Artery Embolization(UAE) Versus High-Intensity-Focused-Ultrasound(HIFU) for… | N/A | terminated | Apr 18, 2013 | Chinese University of Hong Kong | not stated | Not stated |
| NCT02012192 | GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer | Phase 1 / Phase 2 | terminated | Dec 16, 2013 | Medical University Innsbruck | production of IMP has stopped | Other (stated, no rule matched) |
| NCT03210324 | A Study on the Mifepristone Tablets in the Treatment of Symptomatic Uterine Fibroids With… | Phase 4 | terminated | Jul 6, 2017 | China Resources Zizhu Pharmaceutical Co., Ltd. | It is difficult to recruit enough participants | Enrollment / accrual |
| NCT03613493 | Acceptability of Human Papillomavirus (HPV) Self-sampling Tools for Cervical Cancer… | N/A | terminated | Aug 3, 2018 | University of Miami | Budgetary and Timing Constraints | Funding |
| NCT01144442 | WCC# 59 Hyperthermic Intraperitoneal Chemotherapy Utilizing Carboplatin in First… | N/A | terminated | Jun 15, 2010 | Masonic Cancer Center, University of Minnesota | PI Request | Other (stated, no rule matched) |
| NCT00262821 | Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With… | Phase 3 | terminated | Dec 7, 2005 | National Cancer Institute (NCI) | Study drug no longer available resulting in lack of study drug for participants. | Other (stated, no rule matched) |
| NCT02811159 | An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the… | Phase 2 | terminated | Jun 23, 2016 | Repros Therapeutics Inc. | Business decision | Sponsor / business decision |
| NCT03836157 | Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer | Phase 2 | withdrawn | Feb 11, 2019 | University of Oklahoma | Study was not initiated. | Other (stated, no rule matched) |
| NCT02367352 | Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With… | Phase 1 | terminated | Feb 20, 2015 | Millennium Pharmaceuticals, Inc. | Sponsor's decision | Sponsor / business decision |
| NCT02558348 | Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial,…(AL3818) | Phase 1 / Phase 2 | terminated | Sep 24, 2015 | Advenchen Laboratories, LLC | Sponsor termination | Other (stated, no rule matched) |
| NCT01159067 | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and… | Phase 2 | terminated | Jul 9, 2010 | City of Hope Medical Center | Low enrollment | Enrollment / accrual |
| NCT02153905 | T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who… | Phase 1 / Phase 2 | terminated | Jun 3, 2014 | National Cancer Institute (NCI) | Slow, insufficient accrual. | Enrollment / accrual |
| NCT01958112 | GSK1120212+GSK2141795 for Cervical Cancer | Phase 2 | terminated | Oct 8, 2013 | Dana-Farber Cancer Institute | Drug supply | Drug supply |
| NCT02907073 | Positron Emission Tomography (PET) Imaging Studies With NIS Reporter | Phase 1 / Phase 2 | terminated | Sep 20, 2016 | Mayo Clinic | pursuing IND | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Apr 24, 2020source: clinicaltrials